Evidence map›Paper›PMID 39962849›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Research Progress of ALK Activation Pattern Changes and Targeted Therapy 
in Advanced Lung Cancer].

Aojiao Wei, Bo Jiang, Yurong Huang, Mengyun Liu, Jing Yan, Yuanyuan Zhao, Wenjie He

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aojiao WeiKunming Medical University, Kunming 650500, China.
Bo JiangDepartment of Geriatric Oncology, The Third Affiliated Hospital of 
Kunming Medical University, Kunming 650118, China.
Yurong HuangKunming Medical University, Kunming 650500, China.
Mengyun LiuKunming Medical University, Kunming 650500, China.
Jing YanKunming Medical University, Kunming 650500, China.
Yuanyuan ZhaoKunming Medical University, Kunming 650500, China.
Wenjie HeDepartment of Geriatric Oncology, The Third Affiliated Hospital of 
Kunming Medical University, Kunming 650118, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most common cancer in China and even in the world, and it is also the main cause of cancer death. Patients with anaplastic lymphoma kinase (ALK) gene alterations have the opportunity to receive molecularly targeted therapies. The inhibitors of anaplastic lymphoma kinase, such as ALK-tyrosine kinase inhibitors (ALK-TKIs) significantly prolong the survival of patients. ALK gene variant types include point mutation, amplification, fusion/rearrangement, and ALK fusion is more common than other types. However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction.
.

Indexed as

Lung NeoplasmsMolecular Targeted TherapyReceptor Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseHumansProtein Kinase InhibitorsALK protein, humanAnaplastic Lymphoma KinaseProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesAnaplastic lymphoma kinaseAnaplastic lymphoma kinase activation patten changeAnaplastic lymphoma kinase inhibitorsLung neoplasmsTargeted therapy

Identifiers

PMID39962849
PMCPMC11839494

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.